CMA hails TGA CM ticks
September 14, 2015
approval by the Therapeutic
Goods Administration (TGA)
of ten new ingredients for use
in listed medicines has been
welcomed by Complementary
Medicines Australia (CMA) which
has advocated for removal of
redundant regulatory burden.
The listing notice, published
by the TGA on Fri, includes
preparations that contain ribose,
calcium pyruvate, magnesium
pyruvate, octanoic acid, Terminalia
arjuna, Berberis aristata, comethylcobalamin,
choline
dihydrogen citrate, Liepidium
meyenii, Trachyspermum ammi and
dimethylglycine hydrocholoride as
a therapeutically active ingredient.
CMA ceo Carl Gibson said: “We
welcome this streamlining of
ingredient approvals, resulting
from recent work by the TGA
towards greater collaboration with
comparable international regulators
and with industry.
“It is important to enhance
competition and innovation in the
industry by removing unnecessary
regulation, whilst maintaining
consumer confidence in the
exceptional reputation of the
Australian regulatory system.”
With many ingredients found safe
overseas previously unavailable
here, Australians “have been
missing out on innovative new
products,” Gibson said.
“The complementary medicines
industry is driven by consumers,
meaning that the ability to innovate
is vital to the sustainability of the
complementary medicines industry,
enabling companies to produce
new products and meet consumer
demands.”
“With an appropriate regulatory
environment, the Australian
complementary medicines industry
will continue to grow and support
high skilled manufacturing and local
jobs,” he concluded.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Sep 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Sep 15
